Barr Pharma Subsidiary PLIVA Receives Approval for Generic ZITHROMAX(R) IV, 500 mg Vial

Co announces that PLIVA has rec'd final approval from the F.D.A for its Abbreviated New Drug Application to manufacture and market Azithromycin for Injection, 500 mg vial, the generic version of Pfizer Labs' ZITHROMAX IV. Co intends to launch its product during 1Q07. The co's Azithromycin for Injection, 500 mg vial will compete in a mkt that had total U.S. sales of approx $75 mln, based on I.M.S data for the 12-month period ending Nov 2006.